Surgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of “Moderate Buy” by Analysts

Surgery Partners, Inc. (NASDAQ:SGRY) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $37.38.

A number of analysts recently issued reports on SGRY shares. Benchmark reiterated a “buy” rating and issued a $50.00 price target on shares of Surgery Partners in a report on Monday, August 26th. JPMorgan Chase & Co. lowered their target price on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday, December 3rd. Royal Bank of Canada cut their price target on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. UBS Group began coverage on Surgery Partners in a report on Monday, October 14th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Macquarie reiterated an “outperform” rating and set a $34.00 target price on shares of Surgery Partners in a report on Tuesday, November 19th.

Surgery Partners Stock Up 0.5 %

NASDAQ:SGRY opened at $20.36 on Friday. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -42.42, a price-to-earnings-growth ratio of 17.95 and a beta of 2.58. Surgery Partners has a twelve month low of $19.90 and a twelve month high of $36.92. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. The stock has a fifty day simple moving average of $26.93 and a 200-day simple moving average of $27.95.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). The company had revenue of $770.40 million for the quarter, compared to the consensus estimate of $768.99 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 EPS. Analysts anticipate that Surgery Partners will post 0.71 EPS for the current year.

Hedge Funds Weigh In On Surgery Partners

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. King Street Capital Management L.P. purchased a new stake in shares of Surgery Partners during the third quarter valued at about $46,748,000. Royce & Associates LP lifted its position in Surgery Partners by 12.2% during the third quarter. Royce & Associates LP now owns 510,261 shares of the company’s stock valued at $16,451,000 after acquiring an additional 55,545 shares during the last quarter. Lombard Odier Asset Management Europe Ltd acquired a new stake in Surgery Partners in the second quarter valued at approximately $4,163,000. Principal Financial Group Inc. purchased a new position in Surgery Partners in the third quarter worth $1,469,000. Finally, Rhumbline Advisers grew its holdings in Surgery Partners by 19.6% in the second quarter. Rhumbline Advisers now owns 127,952 shares of the company’s stock worth $3,044,000 after purchasing an additional 20,963 shares during the last quarter.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.